|
|
 |
|
Total Number of Holdings (excluding cash): 30
| Alkermes Plc |
ALKS |
G01767105 |
Health Care |
2,547,826 |
$81,148,258.10 |
4.49% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Health Care |
3,595,956 |
$78,535,679.04 |
4.34% |
| Sarepta Therapeutics, Inc. |
SRPT |
803607100 |
Health Care |
900,890 |
$74,773,870.00 |
4.13% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Health Care |
340,128 |
$71,185,389.12 |
3.94% |
| Seagen Inc. |
SGEN |
81181C104 |
Health Care |
412,629 |
$70,225,329.51 |
3.88% |
| Moderna, Inc. |
MRNA |
60770K107 |
Health Care |
210,789 |
$69,956,653.32 |
3.87% |
| QIAGEN N.V. |
QGEN |
N72482123 |
Health Care |
1,277,718 |
$66,198,569.58 |
3.66% |
| Bio-Techne Corporation |
TECH |
09073M104 |
Health Care |
131,575 |
$65,504,613.75 |
3.62% |
| BioNTech SE (ADR) |
BNTX |
09075V102 |
Health Care |
260,915 |
$65,314,851.95 |
3.61% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Health Care |
635,949 |
$65,267,445.87 |
3.61% |
| Nektar Therapeutics |
NKTR |
640268108 |
Health Care |
3,749,909 |
$64,010,946.63 |
3.54% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Health Care |
157,086 |
$63,751,782.24 |
3.52% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Health Care |
326,701 |
$61,289,107.60 |
3.39% |
| IQVIA Holdings Inc. |
IQV |
46266C105 |
Health Care |
243,907 |
$60,201,125.74 |
3.33% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Health Care |
880,304 |
$59,992,717.60 |
3.32% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Health Care |
766,182 |
$59,394,428.64 |
3.28% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Health Care |
103,381 |
$57,440,551.22 |
3.18% |
| Ultragenyx Pharmaceutical Inc. |
RARE |
90400D108 |
Health Care |
708,003 |
$57,348,243.00 |
3.17% |
| Ionis Pharmaceuticals, Inc. |
IONS |
462222100 |
Health Care |
1,652,752 |
$57,003,416.48 |
3.15% |
| Grifols, S.A. (ADR) |
GRFS |
398438408 |
Health Care |
3,852,842 |
$54,517,714.30 |
3.01% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Health Care |
298,507 |
$54,298,423.30 |
3.00% |
| Biogen Inc. |
BIIB |
09062X103 |
Health Care |
186,175 |
$53,108,280.50 |
2.94% |
| Illumina, Inc. |
ILMN |
452327109 |
Health Care |
129,785 |
$52,965,258.50 |
2.93% |
| Exact Sciences Corporation |
EXAS |
30063P105 |
Health Care |
529,882 |
$51,795,965.50 |
2.86% |
| Incyte Corporation |
INCY |
45337C102 |
Health Care |
771,106 |
$50,723,352.68 |
2.80% |
| Agios Pharmaceuticals, Inc. |
AGIO |
00847X104 |
Health Care |
1,078,115 |
$50,380,313.95 |
2.79% |
| Amgen Inc. |
AMGN |
031162100 |
Health Care |
243,459 |
$50,342,452.02 |
2.78% |
| FibroGen, Inc. |
FGEN |
31572Q808 |
Health Care |
4,209,976 |
$48,456,823.76 |
2.68% |
| bluebird bio, Inc. |
BLUE |
09609G100 |
Health Care |
2,256,031 |
$46,496,798.91 |
2.57% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Health Care |
2,570,650 |
$45,808,983.00 |
2.53% |
| US Dollar |
$USD |
|
Other |
1,140,427 |
$1,140,426.90 |
0.06% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|